Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
XFOR - X4 Pharmaceuticals Inc
$8.50
0.35(4.29%)9:00:00 PM 1/15/2021
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Stock Chart

Summary:

  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/7/2021XFOR
    X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference

    BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.   A webcast of the on-demand presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com and at Presenta...

    01/4/2021XFOR
    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on December 31, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusivel...

    12/18/2020XFOR
    X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher

    X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    12/14/2020XFOR
    X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer

    BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company's clinical development programs. “We are very pleased to welcome Diego to our team,” said Paula Ragan, Ph.D., Presid...

    12/10/2020XFOR
    X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome

    BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has received Rare Pediatric Disease (RPD) Designation from the U.S. Food and Drug Administration (FDA) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary imm...

    12/8/2020XFOR
    Is XFOR A Good Stock To Buy Now?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

    11/10/2020XFOR
    X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

    BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 8:40 am Eastern Time, and conduct one-on-one investor meetings around the event. Details are as follows: Conference: Stifel 2020 Virtual...

    11/5/2020XFOR
    X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

    WHIM Phase 2 data published in ‘Blood’ - the Official Journal of the American Society of Hematology Granted Fast Track Designation by FDA for mavorixafor in WHIM syndromeKey leadership appointments including CSO and Board Director Conference call today at 8:30 a.m. ETBOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported fina...